Structure Therapeutics (NASDAQ:GPCR) vs. Kodiak Sciences (NASDAQ:KOD) Head to Head Comparison

Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Profitability

This table compares Structure Therapeutics and Kodiak Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-26.08%	-24.65%
Kodiak Sciences	N/A	-246.20%	-78.44%

Analyst Recommendations

This is a summary of recent ratings and target prices for Structure Therapeutics and Kodiak Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2	0	12	1	2.80
Kodiak Sciences	1	2	5	0	2.50

Structure Therapeutics presently has a consensus target price of $104.40, suggesting a potential upside of 11.31%. Kodiak Sciences has a consensus target price of $26.57, suggesting a potential downside of 0.52%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Kodiak Sciences.

Institutional and Insider Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Structure Therapeutics has a beta of -2.05, suggesting that its share price is 305% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500.

Earnings and Valuation

This table compares Structure Therapeutics and Kodiak Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$122.53 million	($1.22)	-76.88
Kodiak Sciences	N/A	N/A	-$176.21 million	($4.12)	-6.48

Structure Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Structure Therapeutics beats Kodiak Sciences on 9 of the 12 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Kodiak Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.